Article Text

Download PDFPDF
Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications
  1. Ludvig M Sollid1,
  2. Frits Koning2
  1. 1Department of Immunology, University of Oslo, Oslo, Norway
  2. 2Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Dr Ludvig M Sollid, Department of Immunology, University of Oslo, Oslo, Norway; l.m.sollid{at}medisin.uio.no; Dr Frits Koning, Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands; f.koning{at}lumc.nl

Statistics from Altmetric.com

We read with interest the letter to the editor by Massier et al1 and the accompanying response by Fasano.2 We would like to point out one critical issue that has not been addressed, namely, the relationship between AT1001, zonulin and prehaptoglobin-2. AT1001 is an octapeptide that was thought to represent the N-terminal sequence of zonulin.3 4 However, in all likelihood this octapeptide sequence (GGVLVQPG) derives from immunoglobulin. In their attempt to identify the human homolog of the Vibrio cholera zonula occludens toxin …

View Full Text

Footnotes

  • LMS and FK contributed equally.

  • Contributors LS and FK are equal contributors to this article.

  • Funding LMS is funded in part by the Stiftelsen KG Jebsen (SKGJ-MED-017) and a grant from the South-Eastern Norway Regional Health Authority (project #2020027). FK is funded in part by the collaboration project TIMID (LSHM18057-SGF) financed by the PPP allowance made available by Top Sector Life Sciences and Health to Samenwerkende Gezondheidsfondsen (SGF).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.